Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance

Journal of Cystic Fibrosis

Volumn 10, Issue 6, 2011, Pages 422-427

  Goncalves Vidigal, P ^a   Grosse Onnebrink, J ^a   Mellies, U ^a   Buer, J ^a   Rath, P M ^a   Steinmann, J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cystic fibrosis; S. maltophilia; Selective agar; Susceptibility testing

Indexed keywords

CEFTAZIDIME; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; TICARCILLIN; TICARCILLIN PLUS CLAVULANATE ACID; TIGECYCLINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGAR MEDIUM; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CHILD; CYSTIC FIBROSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SPUTUM ANALYSIS; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; AGAR; AGED; ALGORITHMS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CULTURE MEDIA; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 81455154554     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.06.010     Document Type: Article

References (26)

1. Hauser A.R., Jain M., Bar-Meir M., McColley S.A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011, 24:29-70.
2. de Vrankrijker A.M., Wolfs T.F., van der Ent C.K. Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010, 11:246-254.
3. Palleroni N.J., Bradbury J.F. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol 1993, 43:606-609.
4. Blessing J., Walker J.E., Maybury B., Yeager A.S., Lewiston N. Pseudomonas cepacia and maltophilia in the cystic fibrosis patient. Am Rev Respir Dis 1979, 119:262. abstr.
5. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
6. Paez J.I., Costa S.F. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 2008, 70:101-108.
7. Waters V., Yau Y., Prasad S., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response on effect on lung disease. Am J Respir Crit Care Med 2011, 183:635-640.
8. Laine L., Perry J.D., Lee J., et al. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients. J Cyst Fibros 2009, 8:143-149.
9. da Silva Filho L.V., Velloso L. de F., Bento C.N., et al. Use of selective medium for Burkholderia cepacia isolation in respiratory samples from cystic fibrosis patients. Rev Inst Med Trop Sao Paulo 2002, 44:203-208.
10. Horré R., Marklein G., Siekmeier R., Nidermajer S., Reiffert S.M. Selective isolation of Pseudallescheria and Scedosporium species from respiratory tract specimens of cystic fibrosis patients. Respiration 2009, 77:320-324.
11. San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:168-171.
12. Kerr K.G., Denton M., Todd N., Corps C.M., Kumari P., Hawkey P.M. A new selective differential medium for isolation of Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 1996, 15:607-610.
13. Greisen K., Loeffelholz M., Purohit A., Leong D. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J Clin Microbiol 1994, 32:335-351.
14. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Eighth Edition. CLSI document M07-A8 2009, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
15. Andrews J.M. Working party on susceptibility testing. BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 2009, 64:454-489.
16. Juhnke M.E., des Jardin E. Selective medium for isolation of Xanthomonas maltophilia from soil and rhizosphere environments. Appl Environ Microbiol 1989, 55:747-750.
17. Denton M., Hall M.J., Todd N.J., Kerr K.G., Littlewood J.M. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium. Clin Microbiol Infect 2000, 6:397-398.
18. Foster N.F., Chang B.J., Riley T.V. Evaluation of a modified selective differential medium for the isolation of Stenotrophomonas maltophilia. J Microbiol Methods 2008, 75:153-155.
19. Hogardt M., Häußler S., Balke B., et al. Selektivmedien und spezialkultur. Mikrobiologisch-infektiologische Qualitätsstandards (MiQ) 2006, Elsevier Urban & Fischer, München.
20. Antibiotic treatment for cystic fibrosis. Section7.3: Respiratory infection with Stenotrophomonas maltophilia 2009, UK Cystic Fibrosis Trust Antibiotic Working Group, Cystic Fibrosis Trust, Bromley, Kent, UK. 3rd ed.
21. Goss C.H., Otto K., Aitken M.L., Rubenfeld G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356-361.
22. Woodruff H.B., Mata J.M., Hernández S., et al. Fosfomycin: laboratory studies. Chemotherapy 1977, 23(Suppl. 1):1-22.
23. Cantón R., Valdezate S., Vindel A., Sánchez Del Saz B., Maíz L., Baquero F. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and difference with noncystic fibrosis isolates. Pediatr Pulmonol 2003, 35:99-107.
24. Nazik H., Öngen B., Erturan Z., Salcioǧlu M. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients. Jpn J Infect Dis 2007, 60:82-86.
25. McKnight A.J., Shaw A., Goldsmith C.E., et al. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomas maltophilia isolated from cystic fibrosis patients in Northern Ireland. Br J Biomed Sci 2005, 62:30-32.
26. King P., Lomovskaya O., Griffith D.C., Burns J.L., Dudley M.N. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010, 54:143-148.